US FDA authorises lower intravenous and subcutaneous dose of REGEN-COV (casirivimab and imdevimab) antibody to treat Covid-19

The FDA originally authorised a 2.4g single IV dose for the treatment of non-hospitalised patients with Covid-19. The Agency has now lowered the dose to 1.2g and permitted administration via subcutaneous injection when IV infusion is not possible and would lead to treatment delay

Source:

Reuters Health